CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) indication : treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features

The CADTH Canadian Drug Expert Committee (CDEC) recommends that ocrelizumab be reimbursed for the treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2017, November 21, 2017
Edition:Version 1.0
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that ocrelizumab be reimbursed for the treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features
Item Description:"Final."
Physical Description:1 PDF file (8 pages)